About PrognomiQ
PrognomiQ is a company based in San Mateo (United States) founded in 2020 by Philip Ma and Omid Farokhzad. PrognomiQ has raised $102.24 million across 4 funding rounds from investors including Fidelity Investments, T. Rowe Price and Bruker. The company has 24 employees as of December 31, 2021. PrognomiQ offers products and services including Multi-Omics Tests and Proteomic Data Services. PrognomiQ operates in a competitive market with competitors including PreOmics, Vivostat, LenioBio, ACRO Biosystems and List Biological Laboratories, among others.
- Headquarter San Mateo, United States
- Employees 24 as on 31 Dec, 2021
- Founders Philip Ma, Omid Farokhzad
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Prognomiq, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$102.24 M (USD)
in 4 rounds
-
Latest Funding Round
$11.87 M (USD), Series D
Jan 02, 2026
-
Investors
Fidelity Investments
& 9 more
-
Employee Count
24
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of PrognomiQ
PrognomiQ offers a comprehensive portfolio of products and services, including Multi-Omics Tests and Proteomic Data Services.
Enables early detection of diseases using integrated proteomics data.
Provides insights into disease mechanisms via large-scale protein analysis.
People of PrognomiQ
Unlock access to complete
Unlock access to complete
Funding Insights of PrognomiQ
PrognomiQ has successfully raised a total of $102.24M across 4 strategic funding rounds. The most recent funding activity was a Series D round of $11.87 million completed in January 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in PrognomiQ
PrognomiQ has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, T. Rowe Price and Bruker.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital is provided to biomedical technology startups.
|
Locked | Locked | Locked | |
|
Venture capital investments in healthcare are focused on by aMoon.
|
Locked | Locked | Locked | |
|
Long-term private equity investments in transformational opportunities are pursued.
|
Locked | Locked | Locked |
Investor details for PrognomiQ
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by PrognomiQ
Investment portfolio details for PrognomiQ
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - PrognomiQ
Detailed financials for PrognomiQ
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Prognomiq Comparisons
Peer comparison for PrognomiQ
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of PrognomiQ
PrognomiQ operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as PreOmics, Vivostat, LenioBio, ACRO Biosystems and List Biological Laboratories, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Reagents and instruments for proteomics research are supplied by PreOmics.
|
|
| Locked | Locked | Locked |
On-site fibrin sealant preparation systems are developed and provided.
|
|
| Locked | Locked | Locked |
Kits for cell-free eukaryotic protein expression are provided.
|
|
| Locked | Locked | Locked |
Recombinant proteins are manufactured to support cancer immunotherapy efforts.
|
|
| Locked | Locked | Locked |
Specializes in the production of research reagents
|
Detailed competitors of PrognomiQ
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Prognomiq
Complete news archive for PrognomiQ
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PrognomiQ
PrognomiQ was founded in 2020 and raised its 1st funding round 2 years after it was founded.
PrognomiQ is headquartered in San Mateo, United States. It is registered at San Mateo, California, United States.
Philip Ma is the current CEO of PrognomiQ. They have also founded this company.
PrognomiQ is a funded company, having raised a total of $102.24M across 4 funding rounds to date.
As of Dec 31, 2021, the latest employee count at PrognomiQ is 24.
Founded in 2020 and headquartered in San Mateo, United States, PrognomiQ operates in the health technology sector. Diagnostic tests are developed by the company to identify cancer and other diseases at early stages. Proteomic data is integrated with genomic, metabolomic, and additional health information to support detection and treatment strategies. Operations focus on advancing personalized medicine through multi-omics approaches.
PrognomiQ offers Multi-Omics Tests and Proteomic Data Services.
PrognomiQ has 10 investors. Key investors include Fidelity Investments, T. Rowe Price, Bruker, Seer, and Catalio Capital Management.